Edgewise Therapeutics, Inc.
EWTX
$33.76
-$0.25-0.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.44% | 32.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.33% | 19.47% | |||
| Operating Income | 3.33% | -19.47% | |||
| Income Before Tax | 2.40% | -23.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.40% | -23.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.40% | -23.48% | |||
| EBIT | 3.33% | -19.47% | |||
| EBITDA | 3.38% | -19.68% | |||
| EPS Basic | 3.40% | -22.88% | |||
| Normalized Basic EPS | 3.41% | -22.91% | |||
| EPS Diluted | 3.40% | -22.88% | |||
| Normalized Diluted EPS | 3.41% | -22.91% | |||
| Average Basic Shares Outstanding | 1.04% | 0.49% | |||
| Average Diluted Shares Outstanding | 1.04% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||